Inclusion Criteria:  • HIV-1 infected patients > 18 years  Antiretroviral treatment switch to BIC/FTC/TAF decided in standard care by physician Kidney transplant recipient ≥ 3 months Receiving calcineurin and/or mTOR inhibitors without change in doses ≥ 4 weeks Plasma HIV RNA ≤ 50 cpml ≥ 6 months (1 blip permitted 200cp/ml) eGFR (CKD-EPI) ≥ 30 ml/mn/1.73m2 Written consent GSS to BIC/FTC/TAF ≥ 2 Active contraception in potential child-bearing women  Exclusion Criteria:  Allergy or intolerance to one of the following drug or to any of excipients: FTC, TDF, INSTI Current ART containing TAF HIV-2 or HIV-1/HIV-2 co-infection Patients with severe hepatic impairment (Child-Pugh Class C) Patient without health coverage Pregnancy and breast-feeding